Detailing Characteristic of Fibrostenotic Crohn’s Disease Biology & the Potential of Locally Activated Pro-Drug PDE4 Inhibitor to Minimize OffTarget Effects & Maximize Therapeutic Efficacy
Time: 2:30 pm
day: Day Two
Details:
- Discussing the prevalence and clinical presentation of fibrostenotic Crohn’s disease, and the underlying biological mechanisms, focusing on fibrosis pathways and the role of chronic inflammation in disease progression
- Describing the mechanism of the PDE4 inhibitor and its dual antifibrotic and anti-inflammatory properties
- The innovative pro-drug approach allowing for local activation in the colon or distal small intestine, aiming to reduce systemic side effects and improve drug specificity
